BioRestorative Therapies, Inc. (BRTX)
| Previous close | 1.4800 |
| Open | 1.4400 |
| Bid | 1.3500 x 200 |
| Ask | 1.5300 x 400 |
| Day's range | 1.3951 - 1.4400 |
| 52-week range | 1.2000 - 7.1300 |
| Volume | |
| Avg. volume | 590,450 |
| Market cap | 9.682M |
| Beta (5Y monthly) | 61.68 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
- Company to provide update on exciting new commercial agreement, as well as Phase 2 clinical trial in Spine and preclinical development program in Obesity - MELVILLE, N.Y., April 30, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that it will release its first quarter 2024 financial results after market close on Tuesday, May 14, 2024. "I look forward
- GlobeNewswire
BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology
— Leading regenerative medicine and aesthetics innovators collaborate to build a vertically integrated, best-in-class biocosmeceutical platform — — Exclusive, five (5)-year agreement includes BioRestorative supplying its initial commercial product to Cartessa — — Financial impact from commercial partnership expected to provide flexibility for BioRestorative to become significantly less dependent on the capital markets for future funding — MELVILLE, N.Y., April 30, 2024 (GLOBE NEWSWIRE) -- BioRes
- GlobeNewswire
BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
— Amendment replaces saline injections with sham injections in the control group — MELVILLE, N.Y., April 16, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared an important amendment to the protocol of the ongoing Phase 2 study investigating the use of BRTX-100, the Company’s lead cell therapy
